Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00076089 · ClinicalTrials.gov registry record · Phase 3
OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)
A Phase 3 study of Chronic Obstructive Pulmonary Disease and COPD, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,100
- Enrollment target
- 20
- Study locations
NCT00076089: Completed Phase 3 study of Chronic Obstructive Pulmonary Disease and COPD, sponsored by AstraZeneca.
NCT00076089 is a Phase 3 study of Chronic Obstructive Pulmonary Disease and COPD that has completed, run by AstraZeneca. The registered enrollment target is 1,100 participants, below the 1,741-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 20 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00076089, a Phase 3 study of Chronic Obstructive Pulmonary Disease and COPD, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG Roflumilast
Study Locations (20)
Alabama
- ALTANA Pharma - Cities in Alabama
Arizona
- ALTANA Pharma - Cities in Arizona
Arkansas
- ALTANA Pharma - Cities in Arkansas
California
- ALTANA Pharma - Cities in California
Colorado
- ALTANA Pharma - Cities in Colorado
Connecticut
- ALTANA Pharma - Cities in Connecticut
Florida
- ALTANA Pharma - Cities in Florida
Georgia
- ALTANA Pharma - Cities in Georgia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,100 participants |
| Start Date | 2003-12 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
What the finished NCT00076089 record still lists
NCT00076089 is an interventional study that assigns participants to a tested intervention. Its 1,100 participants enrollment target places it among the larger protocols in the corpus, below the 1,741-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (37% lower).
The record links to 2 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 1 intervention - of which Roflumilast is the first listed.
NCT00076089 names 20 study sites across 20 states, led by Alabama, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00076089 about?
NCT00076089 is a clinical study titled "OPUS Study: Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (BY217/M2-111)". The purpose of this study is to determine whether roflumilast is effective in the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD).
What is the current status of trial NCT00076089?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,100 participants. The study started on 2003-12. Estimated completion is 2005-12.
What conditions does trial NCT00076089 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, COPD.
What interventions are being tested in trial NCT00076089?
The interventions under investigation include: Roflumilast (DRUG).
Who is sponsoring clinical trial NCT00076089?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00076089 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00076089's enrollment target sits among peer trials
1,100 12th of 86 higher than 75 of 86 other Chronic Obstructive Pulmonary Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia